Department of Gastrointestinal and Pediatric Surgery, Division of Reparative Medicine, Institute of Life Sciences, Mie University Graduate School of Medicine, Japan.
Academic Unit of Surgery, School of Medicine, University of Glasgow, Glasgow Royal Infirmary, Glasgow, United Kingdom.
JPEN J Parenter Enteral Nutr. 2018 Nov;42(8):1322-1333. doi: 10.1002/jpen.1171. Epub 2018 May 15.
Sarcopenia is defined as the loss of skeletal muscle mass, accompanied by decreased muscle strength, and consists of myopenia and myosteatosis. Recent evidence has suggested the predictive value of sarcopenia for the risk of perioperative and oncological outcomes in various malignancies. The aim of this study was to clarify the clinical impact of myopenia and myosteatosis in colorectal cancer (CRC) patients.
We analyzed the preoperative psoas muscle mass index and intramuscular adipose tissue content using preoperative computed tomography images from 308 CRC patients using statistical methods.
Despite no significant correlation between myosteatosis and prognosis, preoperative myopenia significantly correlated with clinicopathological factors for disease development, including advanced tumor depth (P = 0.009), presence of lymphatic vessel invasion (P = 0.006), distant metastasis (P = 0.0007), and advanced stage classification (P = 0.013). Presence of preoperative myopenia was an independent prognostic factor for both cancer-specific survival (hazard ratio [HR]: 2.75, 95% confidence interval [CI]: 1.5-5.05, P = 0.001) and disease-free survival (HR: 3.15, 95% CI: 1.8-5.51, P = 0.0001), and was an independent risk factor for postoperative infectious complications in CRC patients (odds ratio: 2.03, 95% CI:1.17-3.55, P = 0.013). Furthermore, these findings were successfully validated using propensity score matching analysis.
Preoperative myopenia could be useful for perioperative management, and quantification of preoperative skeletal muscle mass could identify patients as a high risk for perioperative and oncological outcomes in CRC patients.
肌少症是指骨骼肌量的减少,同时伴有肌肉力量下降,包括肌肉减少症和肌内脂肪增多症。最近的证据表明,肌少症对各种恶性肿瘤围手术期和肿瘤学结局的风险具有预测价值。本研究旨在阐明结直肠癌(CRC)患者中肌少症和肌内脂肪增多症的临床影响。
我们使用统计方法分析了 308 例 CRC 患者术前 CT 图像的竖脊肌质量指数和肌内脂肪含量。
尽管肌内脂肪增多症与预后无显著相关性,但术前肌少症与疾病进展的临床病理因素显著相关,包括肿瘤深度进展(P=0.009)、淋巴管侵犯(P=0.006)、远处转移(P=0.0007)和晚期分期分类(P=0.013)。术前肌少症是癌症特异性生存(风险比[HR]:2.75,95%置信区间[CI]:1.5-5.05,P=0.001)和无病生存(HR:3.15,95% CI:1.8-5.51,P=0.0001)的独立预后因素,也是 CRC 患者术后感染性并发症的独立危险因素(优势比:2.03,95% CI:1.17-3.55,P=0.013)。此外,使用倾向评分匹配分析成功验证了这些发现。
术前肌少症可用于围手术期管理,术前骨骼肌量的定量分析可以识别出具有围手术期和肿瘤学结局高风险的 CRC 患者。